P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

• Paolo Strati,
• Franck Morschhauser,
• Alexey Danilov,
• Chan Cheah,
• Harsh Shah,
• Wojciech Jurczak,
• Damilola Olabode,
• Stefanie Meyer,
• Jeong Lim Yoon,
• Serena Arduini,
• Jamal Saeh,
• Richardp Olsson,
• Gareth Gregory

Affiliations

Paolo Strati

1 The University of Texas MD Anderson Cancer Center, Houston, United States

Franck Morschhauser

2 CHRU Lille – Hôpital Claude Huriez, Lille, France

Alexey Danilov

3 City of Hope Comprehensive Cancer Center, Duarte, United States

Chan Cheah

4 Sir Charles Gairdner Hospital and University of Western Australia, Perth, Australia

Harsh Shah

5 Huntsman Cancer Center, University of Utah, Salt Lake City, United States

Wojciech Jurczak

6 Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

Damilola Olabode

7 AstraZeneca, Waltham, United States

Stefanie Meyer

8 AstraZeneca, Boston, United States

Jeong Lim Yoon

8 AstraZeneca, Boston, United States

Serena Arduini

9 AstraZeneca, Cambridge, United Kingdom

Jamal Saeh

8 AstraZeneca, Boston, United States

Richardp Olsson

10 AstraZeneca, Gothenburg, Sweden

Gareth Gregory

11 Clinical Sciences at Monash Health, Monash University, Melbourne, Australia